Should I buy or sell First Wave BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FWBI shares. View FWBI analyst ratings or view top-rated stocks .

What is First Wave BioPharma's stock price target for 2024?

2 analysts have issued 1 year price targets for First Wave BioPharma's stock. Their FWBI share price targets range from $200.00 to $200.00. On average, they expect the company's share price to reach $200.00 in the next year. This suggests a possible upside of 4,661.9% from the stock's current price. View analysts price targets for FWBI or view top-rated stocks among Wall Street analysts .

How have FWBI shares performed in 2023?

First Wave BioPharma's stock was trading at $122.5840 at the beginning of 2023. Since then, FWBI shares have decreased by 96.6% and is now trading at $4.20. View the best growth stocks for 2023 here .

When is First Wave BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our FWBI earnings forecast .

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma, Inc. (NASDAQ:FWBI) released its earnings results on Monday, November, 13th. The company reported ($9.20) EPS for the quarter, topping the consensus estimate of ($12.40) by $3.20.

When did First Wave BioPharma's stock split?

Shares of First Wave BioPharma reverse split on the morning of Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of First Wave BioPharma?

Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FWBI

First Wave BioPharma (FWBI) Stock Price, News & Analysis

$4.20

-0.49 (-10.45%)

(As of 12/29/2023 ET)

Compare

Today's Range: $4.20
▼
$4.70
50-Day Range: $3.44
▼
$6.60
52-Week Range: $2.75
▼
$179.20

Volume: 376,781 shs
Average Volume: 1.50 million shs
Market Capitalization: $2.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $200.00

First Wave BioPharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 4,661.9% Upside
$200.00 Price Target
Short Interest: Healthy
1.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 14 Articles This Week
Insider Trading: Selling Shares
$1,282 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($49.60) to ($12.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
First Wave BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $200.00, First Wave BioPharma has a forecasted upside of 4,661.9% from its current price of $4.20.
Amount of Analyst Coverage
First Wave BioPharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.81% of the float of First Wave BioPharma has been sold short.
Short Interest Ratio / Days to Cover
First Wave BioPharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in First Wave BioPharma has recently decreased by 96.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
First Wave BioPharma does not currently pay a dividend.
Dividend Growth
First Wave BioPharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FWBI.

3.0

News and Social Media Coverage

News Sentiment
First Wave BioPharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for First Wave BioPharma this week, compared to 1 article on an average week.
Search Interest
5 people have searched for FWBI on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added First Wave BioPharma to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, First Wave BioPharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,282.00 in company stock.
Percentage Held by Insiders
Only 0.49% of the stock of First Wave BioPharma is held by insiders.
Percentage Held by Institutions
Only 2.45% of the stock of First Wave BioPharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for First Wave BioPharma are expected to grow in the coming year, from ($49.60) to ($12.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of First Wave BioPharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of First Wave BioPharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
First Wave BioPharma has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About First Wave BioPharma Stock (NASDAQ:FWBI)

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

FWBI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FWBI Stock News Headlines

December 27, 2023 | markets.businessinsider.com

Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher

December 27, 2023 | msn.com

Why First Wave BioPharma Shares Are Skyrocketing Today

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 27, 2023 | finance.yahoo.com

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

December 27, 2023 | markets.businessinsider.com

First Wave BioPharma To Sell Niclosamide Program To Undisclosed Biopharmaceutical Company

December 27, 2023 | finance.yahoo.com

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

December 20, 2023 | investorplace.com

FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q3 2023

December 20, 2023 | investorplace.com

FWBI Stock Earnings: First Wave BioPharma Reported Results for Q1 2023

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

December 18, 2023 | finance.yahoo.com

UPDATED: First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline

December 18, 2023 | markets.businessinsider.com

First Wave BioPharma To Acquire ImmunogenX In All-stock Transaction

December 18, 2023 | msn.com

First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline

December 18, 2023 | finance.yahoo.com

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

December 14, 2023 | msn.com

First Wave BioPharma approves a 1-for-20 reverse stock split

December 14, 2023 | finanznachrichten.de

First Wave BioPharma, Inc.: First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

December 14, 2023 | finance.yahoo.com

First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

December 6, 2023 | finance.yahoo.com

First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024”

December 5, 2023 | finance.yahoo.com

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference

November 29, 2023 | nz.finance.yahoo.com

First Wave BioPharma, Inc. (3660.F)

November 15, 2023 | usatoday.com

President Biden says 74 Americans have left war-torn Gaza in first day of evacuations

November 3, 2023 | msn.com

First Wave BioPharma files for stock and warrants offering, size not disclosed

October 11, 2023 | seekingalpha.com

First Wave BioPharma CFO discloses sale of 1,676 shares

October 10, 2023 | finance.yahoo.com

Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum

October 3, 2023 | finance.yahoo.com

First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference

September 15, 2023 | finance.yahoo.com

First Wave BioPharma To Present at the BIO Investor Forum

September 14, 2023 | marketwatch.com

First Wave BioPharma Shares Surge 82% on License Agreement with Sanofi

September 14, 2023 | seekingalpha.com

Sanofi in licensing pact with First Wave BioPharma for GIT disorder drug

See More Headlines

Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FWBI
CUSIP: N/A
CIK: 1604191
Web: www.azurrx.com
Phone: (561) 589-7020
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $200.00
High Stock Price Target: $200.00
Low Stock Price Target: $200.00
Potential Upside/Downside: +4,661.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($272.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -652.25%
Return on Assets: -295.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.60
Quick Ratio: 1.60

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $55.12 per share
Price / Book: 0.08

Miscellaneous

Outstanding Shares: 670,000
Free Float: 670,000
Market Cap: $2.81 million
Optionable: Not Optionable
Beta: 1.56

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. James R. Sapirstein M.B.A. (Age 62)
R.Ph., President, CEO & Chairman of the Board
Comp: $576k
Ms. Sarah Romano CPA (Age 42)
Chief Financial Officer
Comp: $419k
Ms. Amy Chandler-Skerkis (Age 54)
Vice President of Regulatory Affairs, QA & Compliance
Mr. Martin Krusin M.B.A.
Senior Vice President of Corporate Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

FWBI Stock Analysis - Frequently Asked Questions

Should I buy or sell First Wave BioPharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FWBI shares.
View FWBI analyst ratings or view top-rated stocks.
What is First Wave BioPharma's stock price target for 2024?: 2 analysts have issued 1 year price targets for First Wave BioPharma's stock. Their FWBI share price targets range from $200.00 to $200.00. On average, they expect the company's share price to reach $200.00 in the next year. This suggests a possible upside of 4,661.9% from the stock's current price.
View analysts price targets for FWBI or view top-rated stocks among Wall Street analysts.
How have FWBI shares performed in 2023?: First Wave BioPharma's stock was trading at $122.5840 at the beginning of 2023. Since then, FWBI shares have decreased by 96.6% and is now trading at $4.20.
View the best growth stocks for 2023 here.
When is First Wave BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our FWBI earnings forecast.

How were First Wave BioPharma's earnings last quarter?: First Wave BioPharma, Inc. (NASDAQ:FWBI) released its earnings results on Monday, November, 13th. The company reported ($9.20) EPS for the quarter, topping the consensus estimate of ($12.40) by $3.20.
When did First Wave BioPharma's stock split?: Shares of First Wave BioPharma reverse split on the morning of Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of First Wave BioPharma?: Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FWBI) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial